DSC
REGN icon

Duncker Streett & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Duncker Streett & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32
Closed -$16.8K – 545
2025
Q2 		$16.8K Buy
+32
New +$17.9K ﹤0.01% 398

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Duncker Streett & Co's REGN Position: Q3 2025 in Review

Duncker Streett & Co sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 32 shares — an estimated $16.8K sold.

Duncker Streett & Co first reported a position in REGN in Q2 2025 and held it in 1 quarter. The position peaked at $16.8K in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Duncker Streett & Co reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Duncker Streett & Co sold 32 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $16.8K.
  • Duncker Streett & Co first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Duncker Streett & Co's Regeneron Pharmaceuticals position peaked at $16.8K in Q2 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Duncker Streett & Co's 13F filing for Q3 2025, filed 23 Oct 2025.